Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, w...
Main Authors: | Ana Raquel-Cunha, Diana Cardoso-Carneiro, Rui M. Reis, Olga Martinho |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/8/5/442 |
Similar Items
-
RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer
by: Maria Gabriela-Freitas, et al.
Published: (2019-11-01) -
Understanding Mechanisms of RKIP Regulation to Improve the Development of New Diagnostic Tools
by: Massimo Papale, et al.
Published: (2022-10-01) -
Insights of RKIP-Derived Suppression of Prostate Cancer
by: Ying Dong, et al.
Published: (2021-12-01) -
RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity
by: Roni Touboul, et al.
Published: (2021-12-01) -
Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma
by: Anna Shvartsur, et al.
Published: (2017-05-01)